4D Molecular Therapeutics Completes Enrollment For Its 4FRONT-2 Second Phase 3 Clinical Trial Evaluating 4D-150 In Patients With Wet Age-Related Macular Degeneration
Benzinga Newsdesk 4 months ago
News
4FRONT-2 global enrollment completed approximately 4 months ahead of initial projections4FRONT-2 over-enrolled (anticipated N>500), with final patient randomization expected in Q3 2026, reflecting strong interest
- 4FRONT-2 global enrollment completed approximately 4 months ahead of initial projections
- 4FRONT-2 over-enrolled (anticipated N>500), with final patient randomization expected in Q3 2026, reflecting strong interest from investigators and patients
- 4FRONT-2 52-week topline data is expected in H2 2027